Franklin Biotechnology Financials
| FBTDX Fund | USD 119.17 0.64 0.53% |
Franklin |
Please note that past performance is not an indicator of the future performance of Franklin Biotechnology, its manager's success, or the effectiveness of its strategy. The performance results shown here may have been adversely or favorably impacted by events and economic conditions that may not prevail in the future. Therefore, you must use caution to infer that these results indicate any fund, manager, or strategy's future performance. Investment returns and principal value will fluctuate so that investors' shares, when sold, may be worth more or less than their original cost.
Franklin Biotechnology Fund Summary
Franklin Biotechnology competes with Vanguard Health, T Rowe, Blackrock Health, Blackrock Health, and Health Care. Under normal market conditions, the fund invests at least 80 percent of its net assets in securities of biotechnology companies and discovery research firms. The fund predominantly invests in equity securities. In addition to its investments in biotechnology companies, the fund may also invest up to 20 percent of its net assets in equity or debt securities of any type of issuer. It is non-diversified.Specialization | Health, Large |
| Instrument | USA Mutual Fund View All |
| Exchange | NMFQS Exchange |
| Business Address | Franklin Strategic Series |
| Mutual Fund Family | Franklin Templeton Investments |
| Mutual Fund Category | Health |
| Benchmark | NYSE Composite |
| Phone | 800 342 5236 |
| Currency | USD - US Dollar |
Franklin Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Franklin Biotechnology's current stock value. Our valuation model uses many indicators to compare Franklin Biotechnology value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Franklin Biotechnology competition to find correlations between indicators driving Franklin Biotechnology's intrinsic value. More Info.Franklin Biotechnology Discovery is rated # 3 fund in price to earning among similar funds. It is one of the top funds in price to book among similar funds fabricating about 0.23 of Price To Book per Price To Earning. The ratio of Price To Earning to Price To Book for Franklin Biotechnology Discovery is roughly 4.37 . Comparative valuation analysis is a catch-all model that can be used if you cannot value Franklin Biotechnology by discounting back its dividends or cash flows. This model doesn't attempt to find an intrinsic value for Franklin Biotechnology's Mutual Fund. Still, instead, it compares the stock's price multiples to a benchmark or nearest competition to determine if the stock is relatively undervalued or overvalued. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Franklin Biotechnology's earnings, one of the primary drivers of an investment's value.Franklin Biotechnology Systematic Risk
Franklin Biotechnology's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Franklin Biotechnology volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was three with a total number of output elements of fifty-eight. The Beta measures systematic risk based on how returns on Franklin Biotechnology correlated with the market. If Beta is less than 0 Franklin Biotechnology generally moves in the opposite direction as compared to the market. If Franklin Biotechnology Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Franklin Biotechnology is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Franklin Biotechnology is generally in the same direction as the market. If Beta > 1 Franklin Biotechnology moves generally in the same direction as, but more than the movement of the benchmark.
Franklin Biotechnology April 25, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Franklin Biotechnology help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Franklin Biotechnology Discovery. We use our internally-developed statistical techniques to arrive at the intrinsic value of Franklin Biotechnology Discovery based on widely used predictive technical indicators. In general, we focus on analyzing Franklin Mutual Fund price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Franklin Biotechnology's daily price indicators and compare them against related drivers.
| Downside Deviation | 1.28 | |||
| Information Ratio | (0.05) | |||
| Maximum Drawdown | 5.33 | |||
| Value At Risk | (2.18) | |||
| Potential Upside | 2.11 |
Check out Investing Opportunities to better understand how to build diversified portfolios, which includes a position in Franklin Biotechnology Discovery. Also, note that the market value of any mutual fund could be tightly coupled with the direction of predictive economic indicators such as signals in unemployment. Note that the Franklin Biotechnology information on this page should be used as a complementary analysis to other Franklin Biotechnology's statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Funds Screener module to find actively-traded funds from around the world traded on over 30 global exchanges.